Telix is supporting continued access to novel PSMA-targeted lutetium therapies through clinical trials and early access programs in Australia and New Zealand, helping men like Mr. Auckland get treatment closer to home. As a founding member of Nuclear Medicines Australia, we are also advocating for the regulatory and reimbursement reform needed to bring these therapies to more patients.
Telix Pharmaceuticals
Verified account This account is verified. Learn more@TelixPharma
Global biopharma company developing radiopharmaceuticals to address unmet medical need in oncology and rare diseases. ASX: TLX | NASDAQ: TLX
614 Following 2K Followers 1.1K Posts
Latest posts 5
For a busy prostate cancer imaging centre, reliable tracer supply is essential.
In this clip from episode two of Radiopharma Unpacked, Dr. Paul Yonover discusses the practical demands of a high-volume service and how generator-produced gallium-68 helps his team manage scheduling and reduce exposure to supply chain disruption.
Watch the full episode here: youtu.be/r3o8maM413o
In this clip from episode two of Radiopharma Unpacked, Dr. Paul Yonover discusses the practical demands of a high-volume service and how generator-produced gallium-68 helps his team manage scheduling and reduce exposure to supply chain disruption.
Watch the full episode here: youtu.be/r3o8maM413o
0:57
In addition to consistently high image quality, 68Ga-PSMA-11 PET offers practical advantages.
In this second episode of Radiopharma Unpacked, Dr. Paul Yonover explains how a same-day workflow suited to high volume services has helped establish gallium-based PSMA-PET as a standard of care in prostate cancer imaging.
Watch the full episode here: youtu.be/r3o8maM413o?si…
In this second episode of Radiopharma Unpacked, Dr. Paul Yonover explains how a same-day workflow suited to high volume services has helped establish gallium-based PSMA-PET as a standard of care in prostate cancer imaging.
Watch the full episode here: youtu.be/r3o8maM413o?si…
1:06
Join Telix’s Managing Director and Group CEO, Dr. Christian Behrenbruch, and CEO of Therapeutics, Richard Valeix, at the upcoming UBS Global Biopharma Conference in London next week.
They will take part in a fireside chat discussing Telix’s growing commercial business, late-stage theranostic pipeline and global, vertically integrated manufacturing and supply chain.
Tune in to the live webcast on November 17 at 9:20 a.m. GMT / 4:20 a.m. EST / 8:20 p.m. AEDT.
Learn more and register: ir.telixpharma.com/events/event-d…
They will take part in a fireside chat discussing Telix’s growing commercial business, late-stage theranostic pipeline and global, vertically integrated manufacturing and supply chain.
Tune in to the live webcast on November 17 at 9:20 a.m. GMT / 4:20 a.m. EST / 8:20 p.m. AEDT.
Learn more and register: ir.telixpharma.com/events/event-d…
Telix is pleased to join Thera4Care – an initiative between 27 European academic, clinical, industry and patient advocacy partners working to advance theranostics and broaden patient access across Europe.
Telix’s FAP-targeting dimer, DOTAGA.Glu.(FAPi)₂, has been selected by the consortium for clinical testing with terbium-161 (¹⁶¹Tb) in a Phase 1 trial in patients with FAP-expressing metastatic solid tumors, initially focused on ovarian and pancreatic cancers and sarcomas.
Read more on our website here: telixpharma.com/news-views/tel…
TLX400-Tx has not received marketing authorization in any jurisdiction.
Telix’s FAP-targeting dimer, DOTAGA.Glu.(FAPi)₂, has been selected by the consortium for clinical testing with terbium-161 (¹⁶¹Tb) in a Phase 1 trial in patients with FAP-expressing metastatic solid tumors, initially focused on ovarian and pancreatic cancers and sarcomas.
Read more on our website here: telixpharma.com/news-views/tel…
TLX400-Tx has not received marketing authorization in any jurisdiction.
0:09